ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib treatment induces the activation of p38 MAPK signaling pathways in BCR-ABL-expressing CML-derived KT-1 cells [21] and K562 cells [35] as examined by Western blotting, suggesting a potential role in imatinib-mediated effects.